Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc. (BCLI) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BCLI · as of Jun 8, 2026
Key Statistics
Explore Brainstorm Cell Therapeutics Inc. Data
bcli stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 3 · Buy rate: 100.0%
Competitors & Peers
bcli competitorsBCLI
ACXP
ADIL
ADXN
BCDA
CDIOStock Performance
Full HistoryAbout Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are spec…
what is brainstorm cell therapeutics inc. · bcli stock overview · brainstorm cell therapeutics inc. company profile · who is brainstorm cell therapeutics inc. ceo · bcli OTC · brainstorm cell therapeutics inc. headquarters · brainstorm cell therapeutics inc. business segments
About Stock Overview & Key Data
Brainstorm Cell Therapeutics Inc. (BCLI) is a Healthcare company in the Biotechnology industry, listed on OTC since Oct 7, 2003. As of the latest trading session, BCLI stock price is $0.80, with a market capitalization of $8.8M. The stock has returned -35.48% over the past 12 months and +45.45% year-to-date.
According to 3 Wall Street analysts, the consensus rating for Brainstorm Cell Therapeutics Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Brainstorm Cell Therapeutics Inc. reported revenue of — and net income of -$10.3M. For detailed data — including Brainstorm Cell Therapeutics Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Brainstorm Cell Therapeutics Inc. (BCLI) stock price is $0.80. The stock is traded on OTC under the ticker symbol BCLI. The 52-week range is $0.46 – $1.33.